



# Officially Licensed **BEST OF ASCO®** INDIA 2026

## 19<sup>th</sup> to 21<sup>st</sup> June 2026 | Jaipur Marriott Hotel



Organizing Committee Chairperson  
**DR. HEMANT MALHOTRA**



Scientific Committee Chairperson  
**DR. PURVISH PARIKH**



Scientific Committee Co-Chairperson  
**DR. AJAY BAPNA**



Organizing Committee Co-Chairperson  
**DR. NARESH SOMANI**



Organizing Committee Co-Chairperson  
**DR. SANDEEP JASUJA**



Program Director  
**DR. ABHISHEK CHARAN**

[CLICK HERE TO REGISTER FOR THE CONFERENCE](#)

CONFERENCE MANAGED BY 



**Day 1 | 19<sup>th</sup> June, 2026 | Friday**

**Main Conference**

**11:30 am to 12:00 pm**

**Press Conference**

**12:00 pm to 12:45 pm**

**Lunch**

**12:45 pm to 1:25pm**

**Academic Session 1 - GU Cancer**

12:45 - 12:50

LBA1: Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): Final analysis of the PROTEUS phase 3 study

12:50 - 12:55

5001: Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study.

12:55 - 1:00

5005: Cognitive effects of darolutamide vs enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology.

1:00 - 1:25

Panel Discussion

1:30 pm to 1:50 pm

Sponsored Symposium

1:50 pm to 2:10 pm

Sponsored Symposium

2:10 pm to 2:30 pm

Sponsored Symposium

**2:30 pm to 3:20 pm**

**Academic Session 2 - Breast Cancer 1**

2:30 - 2:35

500: First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer.

2:35 - 2:40

LBA503: Omission of completion axillary dissection in patients with breast cancer and sentinel lymph node macrometastases: Overall survival and patient-reported arm morbidity from the randomized SENOMAC trial.

2:40 - 2:45

1004: Prevalence of symptomatic skeletal events (SSE) with reduced denosumab (Dmab) dose density (every 12 weeks versus every 4 weeks): A randomized phase III non-inferiority trial SAKK 96/12 REDUSE.

2:45 - 2:50

1005: Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.

2:50 - 3:20

Panel Discussion

3:20 pm to 3:40 pm

Sponsored Symposium

3:40 pm to 4:00 pm

Sponsored Symposium

4:00 pm to 4:20 pm

Sponsored Symposium

4:20 pm to 4:40 pm

Sponsored Symposium

**4:40 pm to 5:20 pm**

**Academic Session 3 - Breast Cancer 2**

4:40 - 4:45

LBA1006: Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2- LA/mBC): Primary analysis of the phase III persevera BC trial.

4:45 - 4:50

LBA1007: First-line (1L) camizestrant (CAMI) for emergent ESR1 mutations (ESR1m) in advanced breast cancer (ABC): Final progression-free survival 2 (PFS2) from the Phase III SERENA-6 trial.

4:50 - 4:55

LBA1000: Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro.



4:55 - 5:20	Panel Discussion
5:25 pm to 5:45 pm	Sponsored Symposium
5:45 pm to 6:05 pm	Sponsored Symposium
6:05 pm to 6:25 pm	Sponsored Symposium
<b>6:25 pm to 7:05 pm</b>	<b>Academic Session 4 - Gynecologic Cancer</b>
6:25 - 6:30	5505: CHRONO: A randomized phase II trial of the chronology of surgery after neoadjuvant chemotherapy for ovarian cancer.
6:30 - 6:35	5506: A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FR $\alpha$ )–high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34).
6:35 - 6:40	5517: Effects of short-term fasting compared to free diet in ovarian cancer patients: Results from a two-arm pilot randomized trial.
6:40 - 7:05	Panel Discussion
7:10 pm to 7:30 pm	Sponsored Symposium
7:30 pm to 7:50 pm	Sponsored Symposium
<b>7:50 pm to 8:30 pm</b>	<b>Academic Session 5 - GU</b> Chairpersons:
7:50 - 7:55	5030: Regional trends in testicular cancer burden among adolescents and young adults (15–39 years), 1990–2023: A Global Burden of Disease analysis.
7:55 - 8:00	4504: Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer.
8:00 - 8:05	108: An AI-based pathology classifier to predict benefit from enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) from ENZAMET (ANZUP 1304).
8:05 - 8:30	Panel Discussion
<b>8:30 pm onwards</b>	<b>Dinner</b>

**Day 2 | 20<sup>th</sup> June, 2026 | Saturday**

**Main Conference**

<b>9:00 am to 9:25 am</b>	<b>Academic Session 6 - GI Cancer 1 (Non-Colorectal)</b>
9:00 - 9:05	LBA4000: Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants (pts) with embolization-eligible unresectable hepatocellular carcinoma (HCC).
9:05 - 9:10	LBA5: Daraxonrasib, a RAS(ON) multi-selective inhibitor, vs chemotherapy in previously treated patients with metastatic pancreatic adenocarcinoma (mPDAC): Primary analysis from the phase 3 RASolute 302 study.
9:10 - 9:25	Panel Discussion
9:25 am to 9:45 am	Sponsored Symposium
9:45 am to 10:05 am	Sponsored Symposium
10:05 am to 10:25 am	Sponsored Symposium
<b>10:25 am to 11:05 am</b>	<b>Academic Session 7 - GI Cancer 2 (Colorectal)</b>
10:25 - 10:30	102: Benefit of adjuvant chemotherapy in resected stage I-IV CRC patients based on ctDNA dynamics across two timepoints: Results from GALAXY study.
10:30 - 10:35	LBA3503: BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).



10:35 - 10:40	LBA3517: AZUR-1: A phase II study of neoadjuvant dostarlimab monotherapy in patients with dMMR/MSI-H locally advanced rectal cancer.
10:40 - 11:05	Panel Discussion
11:05 am to 11:25 am	Sponsored Symposium
11:25 am to 11:45 am	Sponsored Symposium
11:45 am to 12:05 pm	Sponsored Symposium
<b>12:10 pm to 12:50 pm</b>	<b>Academic Session 8 - Hemat - Myeloma</b>
12:10 - 12:15	7501: Phase 3 randomized trial to evaluate the impact of anselamimab on all-cause mortality in $\kappa$ light-chain amyloidosis.
12:15 - 12:20	LBA7506: Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial.
12:20 - 12:25	7507: MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator's choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM).
12:25 - 12:50	Panel Discussion
<b>1:00 pm to 1:50 pm</b>	<b>Lunch</b>
<b>1:50 pm to 2:15 pm</b>	<b>Academic Session 9 - Hemat - NHL and Myelofibrosis</b>
1:50 - 1:55	LBA6500: Selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis: Phase 3 SENTRY trial
1:55 - 2:00	LBA7000: frontMIND: Phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
2:00 - 2:15	Panel Discussion
2:15 pm to 2:35 pm	Sponsored Symposium
2:35 pm to 2:55 pm	Sponsored Symposium
2:55 pm to 3:15 pm	Sponsored Symposium
<b>3:15 pm to 4:05 pm</b>	<b>Academic Session 10 - ImmunoOncology 1</b>
3:15 - 3:20	2502: DART (NCI/SWOG S1609): Comprehensive results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers.
3:20 - 3:25	3143: Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors.
3:25 - 3:30	11000: The association of GLP-1 receptor agonist use with survival and immune-related adverse events in patients receiving immune checkpoint inhibitors: A multi-institutional real-world analysis.
3:30 - 3:35	7008: Mediterranean CD19 genetic variations and potential influence on CAR T-cell therapy efficacy: Implications for population-tailored immunotherapy.
3:35 - 4:05	Panel Discussion
4:10 pm to 4:30 pm	Sponsored Symposium
4:30 pm to 4:50 pm	Sponsored Symposium
4:50 pm to 5:10 pm	Sponsored Symposium
5:10 pm to 5:30 pm	Sponsored Symposium
<b>5:30 pm to 6:20 pm</b>	<b>Academic Session 11 - Lung Cancer 1</b>
5:30 - 5:35	LBA3: Event-Free Survival with Adjuvant Selpercatinib in Stage IB-IIIa RET Fusion-Positive NSCLC: Primary Results of the Phase 3 LIBRETTO-432 Trial
5:35 - 5:40	8000: Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST).



Greenterrere wellness & recreations PVT



Gulab Kiran Seva Samiti



TRANSFORMING HEALTHCARE

5:40 - 5:45	8004: Redefining lung cancer screening eligibility: Smoking duration vs. pack-years in a national VA cohort of nearly 1 million patients.
5:45 - 5:50	8006: Intracranial efficacy of tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): DeLLphi-304 phase 3 post hoc analysis.
5:50 - 6:20	Panel Discussion
<b>6:20 pm to 6:40 pm</b>	<b>Sponsored Symposium</b>
<b>6:40 pm to 7:00 pm</b>	<b>Sponsored Symposium</b>
<b>7:00 pm to 7:50 pm</b>	<b>Academic Session 12 - ImmunoOncology 2</b>
7:00 - 7:05	LBA6007: Ultra-low-dose immunotherapy plus oral metronomic chemotherapy versus paclitaxel-carboplatin in platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma: A randomized phase III trial.
7:05 - 7:10	6002: Metronomic adjuvant chemotherapy (MACE) in locally advanced oral cavity squamous cell carcinoma post-surgery and adjuvant treatment (MACE postop): A phase III randomized controlled trial.
7:10 - 7:15	LBA9505: Updated Outcomes from STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial: ECOG-ACRIN EA6174
7:15 - 7:20	9518: A 3-year landmark overall survival analysis of RP1 plus nivolumab in patients with anti-PD-1–failed melanoma from the IGYTE clinical trial.
7:20 - 7:50	Panel Discussion
<b>7:50 pm to 8:30 pm</b>	<b>Inauguration</b>
<b>8:30 pm onwards</b>	<b>Dinner</b>

**Day 3 | 21<sup>st</sup> June, 2026 | Sunday**

**Main Conference**

<b>9:00 am to 9:40 am</b>	<b>Academic Session 13 - Lung Cancer 2</b>
9:00 - 9:05	LBA4: Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.
9:05 - 9:10	LBA8500: Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28).
9:10 - 9:15	8506: Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1–positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study.
9:15 - 9:40	Panel Discussion
9:45 am to 10:05 am	Sponsored Symposium
10:05 am to 10:25 am	Sponsored Symposium
<b>10:25 am to 11:05 am</b>	<b>Academic Session 14 - Sarcoma</b>
10:25 - 10:30	LBA2: SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.
10:30 - 10:35	11500: Primary results of the phase 3 peak study of bezuclastinib + sunitinib vs sunitinib monotherapy in advanced gastrointestinal stromal tumors (GIST).
10:35 - 10:40	11506: RINGSIDE: A phase 3 randomized, placebo-controlled trial of varegacestat for treatment of progressing desmoid tumors.
10:40 - 11:05	Panel Discussion
<b>11:10 am to 12:00 pm</b>	<b>Academic Session 15 - Head &amp; Neck Cancer</b>



11:10 - 11:15	6000: Adjuvant radiotherapy versus observation following curative surgery for early-stage oral squamous cell carcinoma (AREST; CTRI/2017/07/009114).
11:15 - 11:20	6004: Carboplatin-based versus cisplatin-based induction-concurrent chemoradiotherapy with locoregionally advanced nasopharyngeal carcinoma: A multicenter, parallel-group, non-inferiority, randomized, phase 3 trial.
11:20 - 11:25	6008: Amivantamab in HPV-unrelated recurrent/metastatic head and neck squamous cell cancer after disease progression on immune checkpoint inhibitor and chemotherapy: Pivotal results from the phase 1b/2 OrigAMI-4 study.
11:25 - 11:30	6011: Trastuzumab deruxtecan in patients with HER2-low recurrent/metastatic salivary gland carcinoma: Results from the phase II MYTHOS trial.
11:30 - 12:00	Panel Discussion
12:00 pm to 12:20 pm	Sponsored Symposium
12:20 pm to 12:40 pm	Sponsored Symposium
<b>12:40 pm to 1:30 pm</b>	<b>Academic Session 16 - Oncology Beyond the Obvious (OBTO)</b>
12:40 - 12:45	LBA100: NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening.
12:45 - 12:50	10503: Effect of type and location of BRCA2 deleterious variant on prognosis and survival in metastatic prostate cancer: A longitudinal, international, cohort study from hormone-sensitive to castration-resistant settings.
12:50 - 12:55	10515: Low-dose tamoxifen for pre-cancer and early disease: A pooled analysis by menopausal status.
12:55 - 1:00	11005: Impact of remote therapeutic monitoring with patient-reported outcomes on hospitalization in real-world patients receiving therapy for metastatic solid tumors.
1:00 - 1:30	Panel Discussion
<b>1:30 pm to 2:30 pm</b>	<b>Academic Session 17 - Supportive Care and Public Health</b>
1:30 - 1:35	12000: Dexamethasone reduction or omission with NEPA and olanzapine for HEC: A phase III trial.
1:35 - 1:40	LBA12003: Nationwide randomized, phase III, placebo-controlled trial of bupropion for cancer-related fatigue: Primary outcome results.
1:40 - 1:45	12004: YOCAS yoga, mood disturbance, and insomnia: A URCC NCORP RB nationwide, phase III, randomized, controlled trial with cancer survivors.
1:45 - 1:50	12010: Effect of a weight loss intervention (WLI) on quality of life (QOL) and symptoms in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.
1:50 - 1:55	LBA12008: SUPPORT+ digital self-management and clinical support for advanced cancer: A randomized controlled trial.
1:55 - 2:00	1508: Essential but unaffordable: Real-world costs of WHO essential cancer medicines in a low-income setting.
2:00 - 2:30	Panel Discussion
<b>2:30 pm onwards</b>	<b>Lunch</b>

[CLICK HERE TO REGISTER FOR THE CONFERENCE](#)

CONFERENCE MANAGED BY 



# REGISTRATION DETAILS (GST INCLUSIVE)

Category	Regular (1 <sup>st</sup> May to 31 <sup>st</sup> May 2026)	Spot (1 <sup>st</sup> June 2026 Onwards)
PG Student/Nurse	₹ 4,000/-	₹ 6,000/-
Member of ICON	₹ 10,000/-	₹ 12,000/-
Associate Delegate	₹ 15,000/-	₹ 18,000/-
Industry (Sponsor)	₹ 30,000/-	₹ 40,000/-
Industry (Non-Sponsor)	₹ 2,00,000/-	₹ 2,50,000/-



[CLICK HERE TO REGISTER FOR THE CONFERENCE](#)

CONFERENCE MANAGED BY

